Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

Johnson & Johnson said on Thursday it will discontinue a late-stage study of its add-on treatment for major depressive ...

Sooma announced that it received FDA investigational device exemption (IDE) for its transcranial direct current stimulation ...

Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

Legislation requiring healthcare professionals assess a woman for postpartum depression made it over the first hurdles last ...

The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...

Sooma Medical has received the approval of an investigational device exemption (IDE) from the US Food and Drug Administration ...

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of ...

This summary highlights key global health developments, including J&J halting studies of a depression drug due to low ...

The KOASTAL-1 study failed to achieve its primary endpoint — treatment with Neumora’s drug failed to demonstrate a significant improvement over placebo in alleviating depression symptoms.

Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion ...